Saturday, April 10, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

by Global Biodefense Staff
December 1, 2020
Vaccine Approval Is Just The Beginning – Huge Production Challenges Await

Extensive supply chain and manufacturing challenges await any approved vaccine for COVID-19. Credit: Shutterstock, modified.

Researchers within the Observational Health Data Services and Informatics (OHDSI) community were recently awarded a $10 million contract from the U.S. Food and Drug Administration (FDA) to provide support to the Biologics Effectiveness and Safety (BEST) program, which was launched by the FDA Center for Biologics Evaluation and Research (CBER) in 2017.

The lead research team, primarily comprised of OHDSI personnel from Columbia University, UCLA, and Northeastern University, will provide support to the BEST system in its mission to conduct safety and effectiveness surveillance of biologic products (vaccines, blood and blood products, tissues and advanced therapeutics).

The effort will include serving in a convening role to develop methods related to using observational data from electronic health records and administrative claims to study the effectiveness and safety of biologics, work collaboratively with FDA staff to plan, develop, coordinate, host and convene meetings and workshops, and educate FDA staff and external stakeholders on the BEST infrastructure, capabilities, and applications that serve FDA and stakeholder needs.

“Sound approaches to monitor vaccine safety and effectiveness across large populations have their limitations; this is particularly important with the upcoming roll-out of COVID-19 vaccination programs, and we stand ready to help,” said Marc Suchard, Professor of Biostatistics at UCLA, who will lead methods development under this contract.

With collaborators from more than 30 nations around the world and over one billion patient records across 130 databases mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model, the OHDSI community has both developed open-source tools to produce reliable, reproducible real-world evidence and published studies that have impacted both methodological research (LEGEND principles, ENCePP guidelines) and clinical decision-making (Lancet antihypertensive study, hydroxychloroquine safety profile).

Tags: AwardsEditor PickEpidemiologyVaccine InjuryVaccines

Related Posts

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?
Medical Countermeasures

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

April 8, 2021
New Initiative to Support Studies of the Bat Immune System
Funding News

New Initiative to Support Studies of the Bat Immune System

April 7, 2021
National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder
Medical Countermeasures

National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

April 7, 2021
New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination
Medical Countermeasures

New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination

April 7, 2021
Load More

Latest News

A Virologist Explains Their Concerns About Coronavirus Variants

A Virologist Explains Their Concerns About Coronavirus Variants

April 8, 2021
What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine?

April 8, 2021
New Initiative to Support Studies of the Bat Immune System

New Initiative to Support Studies of the Bat Immune System

April 7, 2021
National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder

April 7, 2021

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
  • Subscribe

© 2021 Stemar Media Group LLC